On January 13, 2026, the U.S. Food and Drug Administration (FDA) announced a landmark decision: the suicidal ideation and behavior (SI/B) warning is being removed from the labeling of GLP-1 receptor agonists Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). The decision follows a comprehensive safety review that found no increased risk of suicidal thoughts or actions associated with these medications.
What data did the FDA review?
The FDA evaluated 91 placebo-controlled trials and a large claims-based cohort study. The conclusion: no statistically significant link between GLP-1 use and suicidal ideation, suicide attempts, or other psychiatric events. The European Medicines Agency (EMA) had already reached the same conclusion in April 2024 after its own investigation.
What does this mean for patients?
The FDA emphasizes that healthcare professionals and patients should be informed about the updated evidence. Removing the warning harmonizes labeling across all GLP-1 products. Diabetes medications such as Ozempic and Mounjaro were never subject to the suicide warning. The agency continues to recommend monitoring mental health changes but states clearly: current data does not support an elevated psychiatric risk.
Background: How did the warning originate?
The original warning was added in 2023/2024 after the FDA's Adverse Event Reporting System received isolated reports of suicidal thoughts from GLP-1 users. This signal was never confirmed in clinical trials or observational studies. The FDA had published a preliminary review in January 2024 but could not rule out a residual risk at that time. The now-available larger datasets allow for a definitive conclusion.
Learn more about GLP-1 safety aspects in our Semaglutide profile and our article on GLP-1 dosing errors and poison control surges.
Not medical advice: This article is for informational purposes only and does not replace individual medical consultation. Consult your healthcare provider for questions about GLP-1 medications.